A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

Oncogene

Volumn 27, Issue 6, 2008, Pages 721-731

  Podar, K ^a   Gouill, S L ^a,b   Zhang, J ^a   Opferman, J T ^c   Zorn, E ^d   Tai, Y T ^a   Hideshima, T ^a   Amiot, M ^b   Chauhan, D ^a   Harousseau, J L ^b   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HÔTEL DIEU   (France)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Apoptosis; Bortezomib; Mcl 1

Indexed keywords

BORTEZOMIB; CASPASE; CASPASE 3; CASPASE 9; DOXORUBICIN; MELPHALAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RELAPSE; CELL CYCLE G1 PHASE; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EMBRYO CELL; FIBROBLAST; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSIENT TRANSFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASES; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; MELPHALAN; MICE; MULTIPLE MYELOMA; NEOPLASM PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; RNA, SMALL INTERFERING; UP-REGULATION;

MURINAE;

EID: 38749138133     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210679     Document Type: Article

References (46)

1. Bae J, Leo CP, Hsu SY, Hsueh AJ. (2000). MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem 275: 25255-25261.
2. Bataille R, Harousseau JL. (1997). Multiple myeloma. N Engl J Med 336: 1657-1664.
3. Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC. (2005). Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4: 686-692.
4. Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R et al. (2004). Targeting mitochondria to overcome conventional and Bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 104: 2458-2466.
5. Chauhan D, Uchiyama H, Akbarali Y, Urashima M, Yamamoto K, Libermann TA et al. (1996). Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood 87: 1104-1112.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17: 393-403.
7. Craig RW. (2002). MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16: 444-454.
8. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL et al. (2002). Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100: 194-199.
9. Domina AM, Smith JH, Craig RW. (2000). Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition. J Biol Chem 275: 21688-21694.
10. Domina AM, Vrana JA, Gregory MA, Hann SR, Craig RW. (2004). MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23: 5301-5315.
11. Gewirtz DA. (1999). A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57: 727-741.
12. Gomez-Bougie P, Bataille R, Amiot M. (2004). The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 34: 3156-3164.
13. Han J, Goldstein LA, Gastman BR, Froelich CJ, Yin XM, Rabinowich H. (2004). Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J Biol Chem 279: 22020-22029.
14. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C et al. (2003a). Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22: 8386-8393.
15. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P et al. (2003b). Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 101: 1530-1534.
16. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. (2001). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61: 3071-3076.
17. Hurley LH. (2002). DNA and its associated processes as targets for cancer therapy. Nat Rev Cancer 2: 188-200.
18. Inoshita S, Takeda K, Hatai T, Terada Y, Sano M, Hata J et al. (2002). Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 277: 43730-43734.
19. Jang YM, Kendaiah S, Drew B, Phillips T, Selman C, Julian D et al. (2004). Doxorubicin treatment in vivo activates caspase-12 mediated cardiac apoptosis in both male and female rats. FEBS Lett 577: 483-490.
20. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. (1993). MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90: 3516-3520.
21. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N et al. (2002). Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62: 4996-5000.
22. Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K et al. (2004a). VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 104: 2886-2892.
23. Le Gouill S, Podar K, Harousseau JL, Anderson KC. (2004b). Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3: 1259-1262.
24. Leu JI, Dumont P, Hafey M, Murphy ME, George DL. (2004). Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6: 443-450.
25. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. (2006). Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
26. Michels J, O'Neill JW, Dallman CL, Mouzakiti A, Habens F, Brimmell M et al. (2004). Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene 23: 4818-4827.
27. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F et al. (2003). Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486.
28. Opferman JT. (2006). Unraveling MCL-1 degradation. Cell Death Differ 13: 1260-1262.
29. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. (2005). Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307: 1101-1104.
30. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. (2003). Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426: 671-676.
31. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. (2005). Phase 1 trial of the proteasome inhibitor Bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105: 3058-3065.
32. Pei XY, Dai Y, Grant S. (2004). Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor Bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852.
33. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. (2006). The proteasome inhibitor Bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and NOXA activation independent of p53 status. Blood 107: 257-264.
34. Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T et al. (2004a). GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood 103: 3474-3479.
35. Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K et al. (2004b). Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by Bortezomib. Cancer Res 64: 7500-7506.
36. Puthier D, Bataille R, Amiot M. (1999). IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29: 3945-3950.
37. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65: 6282-6293.
38. Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H et al. (2005). Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106: 1042-1047.
39. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. (2003). A phase 2 study of Bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617.
40. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. (2000). Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 14: 23-27.
41. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H et al. (2006). Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66: 184-191.
42. Weng C, Li Y, Xu D, Shi Y, Tang H. (2005). Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280: 10491-10500.
43. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. (2005). Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
44. Zamai L, Falcieri E, Zauli G, Cataldi A, Vitale M. (1993). Optimal detection of apoptosis by flow cytometry depends on cell morphology. Cytometry 14: 891-897.
45. Zhang B, Gojo I, Fenton RG. (2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885-1893.
46. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB et al. (1998). Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92: 3226-3239.